MK0457

DRUG4 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Carcinoma, Non-Small-Cell LungChronic Myelogenous LeukemiaChronic Myelogenous Leukemia in Blast CrisisLeukemiaLeukemia, Lymphoblastic, Acute, Philadelphia-PositiveLymphocytic Leukemia, B Cell, AcuteMyelodysplastic SyndromesMyelogenous Leukemia, Chronic

Phase 1

MK0457 in Patients With Leukemia (0457-003)

CompletedNCT00111683

Merck Sharp & Dohme LLCChronic Myelogenous Leukemia in Blast Crisis, Lymphocytic Leukemia, B Cell, Acute, Myelodysplastic Syndromes +1

Start: 2005-06-30End: 2008-05-31Updated: 2015-08-25

A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED)

TerminatedNCT00500006

Merck Sharp & Dohme LLCChronic Myelogenous Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive

Start: 2007-10-31End: 2007-11-30Updated: 2015-01-30

Phase 2

A Phase IIA Study of MK0457 in Patients With Cancer of the Lung (0457-006)

TerminatedNCT00290550

Merck Sharp & Dohme LLCCarcinoma, Non-Small-Cell Lung

Start: 2006-06-30End: 2007-05-31Updated: 2015-07-27

A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008)

TerminatedNCT00405054

Merck Sharp & Dohme LLCLeukemia

Start: 2006-12-31End: 2009-06-30Updated: 2015-01-26